An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Recruiting

Phase 3

Sponsor:

Hoffmann-La Roche

Code:

NCT06047080

Conditions

Large B-Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Glofitamab

Polatuzumab vedotin

Rituximab

Cyclophosphamide

Doxorubicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information